Fibroblast abnormalities in the pathogenesis of systemic sclerosis

Expert Review of Clinical Immunology

Volumn 7, Issue 4, 2011, Pages 491-498

  Usategui, Alicia ^a   Del Rey, Manuel J ^a   Pablos, José L ^a  

^a Universidad Complutense   (Spain)

Author keywords

collagen synthesis; fibroblasts; fibrosis; SMAD; systemic sclerosis; TGF

Indexed keywords

ABELSON KINASE; ALPHA SMOOTH MUSCLE ACTIN; AMYLOID P COMPONENT; CD34 ANTIGEN; CD45 ANTIGEN; EARLY GROWTH RESPONSE FACTOR 1; FOCAL ADHESION KINASE; FRIZZLED PROTEIN; INTERLEUKIN 13; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN EXPRESSION; BONE MARROW CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL NUCLEUS; CELL SUBPOPULATION; CELL TRANSDIFFERENTIATION; CELL TRANSFORMATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROBLAST CULTURE; FIBROCYTE; FIBROSIS; GENE OVEREXPRESSION; HEART MUSCLE FIBROSIS; HYPOXIA; INFLAMMATION; INTRACELLULAR SIGNALING; KIDNEY EPITHELIUM; LUNG ALVEOLUS EPITHELIUM; MESENCHYMAL STEM CELL; METHYLATION; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERICYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TRANSCRIPTION REGULATION;

ANIMALS; AUTOIMMUNITY; CELL GROWTH PROCESSES; CELL TRANSDIFFERENTIATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; FIBROSIS; HUMANS; MOLECULAR TARGETED THERAPY; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 79960910328     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.39     Document Type: Review

References (105)

1. Silver RM. Clinical aspects of localized and systemic scleroderma. Curr Opin. Rheumatol. 3, 973-978 (1991)
2. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 28, 1573-1576 (2001)
3. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 26, 587-595 (2005) (Pubitemid 41726446)
4. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 43, 2437-2444 (2000)
5. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 44, 1359-1362 (2001) (Pubitemid 32537534)
6. Radstake TR, Gorlova O, Rueda B et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet. 42, 426-429 (2010)
7. Dieudé P, Guedj M, Wipff J et al. The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. Arthritis Rheum. 58, 2183-2188 (2008) (Pubitemid 351988112)
8. Rueda B, Broen J, Simeon C et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol. Genet. 18, 2071-2077 (2009)
9. Zhou X, Tan FK, Reveille JD et al. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. Arthritis Rheum. 46, 2990-2999 (2002) (Pubitemid 35315893)
10. Tan FK, Wang N, Kuwana M et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum. 44, 893-901 (2001) (Pubitemid 32319782)
11. Fonseca C, Lindahl GE, Ponticos M et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J. Med 357, 1210-1220 (2007) (Pubitemid 47443180)
12. Rueda B, Simeon C, Hesselstrand R et al. A large multicenter analysis of CTGF -945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype. Ann Rheum. Dis. 68, 1618-1620 (2009)
13. Rogai V, Lories RJ, Guiducci S, Luyten FP, Matucci Cerinic M. Animal models in systemic sclerosis. Clin Exp. Rheumatol. 26, 941-946 (2008)
14. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest. 54, 880-889 (1974)
15. Hitraya EG, Jiménez SA. Transcriptional activation of the a 1(I) procollagen gene in systemic sclerosis dermal fibroblasts. Role of intronic sequences. Arthritis Rheum. 39, 1347-1354 (1996) (Pubitemid 26270094)
16. Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Collagen. Rheum. Dis. Clin North Am. 22, 647-674 (1996)
17. Leroy EC. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J Exp. Med 135, 1351-1362 (1972)
18. Botstein GR, Sherer GK, Leroy EC. Fibroblast selection in scleroderma. An alternative model of fibrosis. Arthritis Rheum. 25, 189-195 (1982) (Pubitemid 12170277)
19. Jelaska A, Arakawa M, Broketa G, Korn JH. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts. Increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum. 39, 1338-1346 (1996) (Pubitemid 26270093)
20. Jimenez SA, Saitta B. Alterations in the regulation of expression of the a 1(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma). Springer Semin. Immunopathol. 21, 397-414 (1999) (Pubitemid 30433749)
21. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor b1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum. 43, 2230-2239 (2000)
22. Santiago B, Galindo M, Rivero M, Pablos JL. Decreased susceptibility to Fas induced apoptosis of systemic sclerosis dermal fibroblasts. Arthritis Rheum. 44, 1667-1676 (2001) (Pubitemid 32642230)
23. Yamakage A, Kikuchi K, Smith EA, LeRoy EC, Trojanowska M. Selective upregulation of platelet-derived growth factor a receptors by transforming growth factor b in scleroderma fibroblasts. J Exp. Med 175, 1227-1234 (1992)
24. Whitfield ML, Finlay DR, Murray JI et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc. Natl Acad. Sci. USA 100, 12319-12324 (2003) (Pubitemid 37271558)
25. Gardner H, Shearstone JR, Bandaru R et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum. 54, 1961-1973 (2006) (Pubitemid 43877946)
26. Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum. 54, 3655-3660 (2006) (Pubitemid 44737178)
27. Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res. Ther. 7, R1113-R1123 (2005)
28. Farina G, Lemaire R, Pancari P, Bayle J, Widom RL, Lafyatis R. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor b. Ann Rheum. Dis. 68, 435-441 (2009)
29. Desmoulière A, Chaponnier C, Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen. 13, 7-12 (2005) (Pubitemid 40250424)
30. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol. 170, 1807-1816 (2007) (Pubitemid 47339255)
31. Hu B, Gharaee-Kermani M, Wu Z, Phan SH. Epigenetic regulation of myofibroblast differentiation by DNA methylation. Am J Pathol. 177, 21-28 (2010)
32. Chesney J, Bacher M, Bender A, Bucala R. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc. Natl Acad. Sci. USA 94, 6307-6312 (1997) (Pubitemid 27270680)
33. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol. 166, 7556-7562 (2001) (Pubitemid 32525636)
34. Shao DD, Suresh R, Vakil V, Gomer RH, Pilling D. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc. Biol. 83, 1323-1333 (2008) (Pubitemid 351960310)
35. Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol. 171, 5537-5546 (2003) (Pubitemid 37432844)
36. Phillips RJ, Burdick MD, Hong K et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 114, 438-446 (2004) (Pubitemid 39071616)
37. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol. 171, 380-389 (2003) (Pubitemid 36745311)
38. Ortonne N, Lipsker D, Chantrel F, Boehm N, Grosshans E, Cribier B. Presence of CD45RO+ CD34+ cells with collagen syntesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hyphotesis. Br J. Dermatol. 150, 1050-1052 (2004) (Pubitemid 38903558)
39. Aiba S, Tabata N, Ohtani H, Tagami H. CD34+ spindle-shaped cells selectively disappear from the skin lesion of scleroderma. Arch Dermatol. 130, 593-597 (1994) (Pubitemid 24150938)
40. Kuwana M, Okazaki Y, Kodama H et al. Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc. Biol. 74, 833-845 (2003) (Pubitemid 38040360)
41. Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin. Rheumatol. 16, 733-738 (2004) (Pubitemid 39425547)
42. Boban I, Barisic-Dujmovic T, Clark SH. Parabiosis and transplantation models show no evidence of circulating dermal fibroblast progenitors in bleomycin-induced skin fibrosis. J Cell Physiol. 214, 230-237 (2008) (Pubitemid 350220077)
43. Ishii G, Sangai T, Sugiyama K et al. In vivo characterization of bone marrow-derived fibroblasts recruited into fibrotic lesions. Stem Cells 23, 699-706 (2005) (Pubitemid 40647266)
44. Ortiz LA, Gambelli F, McBride C et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc. Natl Acad. Sci. USA 100, 8407-8411 (2003) (Pubitemid 36842558)
45. Ninichuk V, Gross O, Segerer S et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int. 70, 121-129 (2006) (Pubitemid 44000128)
46. Cheng Z, Ou L, Zhou X et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol. Ther. 16, 571-579 (2008) (Pubitemid 351314998)
47. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc. Res. 77, 134-142 (2008) (Pubitemid 351195153)
48. Willis BC, Liebler JM, Luby-Phelps K et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-b1: potential role in idiopathic pulmonary fibrosis. Am J Pathol. 166, 1321-1332 (2005) (Pubitemid 40586504)
49. Kim KK, Kugler MC, Wolters PJ et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl Acad. Sci. USA 103, 13180-13185 (2006) (Pubitemid 44338936)
50. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 112, 1776-1784 (2003) (Pubitemid 38063698)
51. Zeisberg EM, Tarnavski O, Zeisberg M et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13, 952-961 (2007) (Pubitemid 47222040)
52. Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM. Activation of microvascular pericytes in autoimmune Raynauds phenomenon and systemic sclerosis. Arthritis Rheum. 42, 930-941 (1999) (Pubitemid 29215003)
53. Rajkumar VS, Shiwen X, Bostrom M et al. Platelet-derived growth factor-b receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol. 169, 2254-2265 (2006) (Pubitemid 351181983)
54. Gay S, Jones RE Jr, Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest. Dermatol. 92, 301-303 (1989) (Pubitemid 19061278)
55. Zheng XY, Zhang JZ, Tu P, Ma SQ. Expression of platelet-derived growth factor B-chain and platelet-derived growth factor b-receptor in fibroblasts of scleroderma. J Dermatol. Sci. 18, 90-97 (1998)
56. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 117, 557-567 (2007) (Pubitemid 46348510)
57. Wynn TA. Fibrotic disease and the T(h)1/T(h)2 paradigm. Nat Rev. Immunol. 4, 583-594 (2004)
58. Distler JH, Jüngel A, Pileckyte M et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum. 56, 4203-4215 (2007) (Pubitemid 350262349)
59. Varga J, Pasche B. Transforming growth factor b as a therapeutic target in systemic sclerosis. Nat Rev. Rheumatol. 5, 200-206 (2009)
60. Roberts AB, Sporn MB, Assoian RK et al. Transforming growth factor type b: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl Acad. Sci. USA 83, 4167-4171 (1986) (Pubitemid 16057012)
61. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor b in human disease. N Engl J. Med 342, 1350-1358 (2000) (Pubitemid 30408720)
62. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-b induces a smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell. Biol. 122, 103-111 (1993) (Pubitemid 23188802)
63. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-b receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-b signalling to scleroderma phenotype. J Invest. Dermatol. 110, 47-51 (1998) (Pubitemid 28086062)
64. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Involvement of avb5 integrin-mediated activation of latent transforming growth factor b1 in autocrine transforming growth factor b signalling in systemic sclerosis fibroblasts. Arthritis Rheum. 52, 2897-2905 (2005) (Pubitemid 41369121)
65. Kubo M, Ihn H, Yamane K, Tamaki K. Upregulated expression of transforming growth factor-b receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J Rheumatol. 29, 2558-2564 (2002) (Pubitemid 35416962)
66. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signalling in scleroderma skin fibroblasts. Arthritis Rheum. 48, 1964-1978 (2003) (Pubitemid 36828692)
67. Dong C, Zhu S, Wang T et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc. Natl Acad. Sci. USA 99, 3908-3913 (2002) (Pubitemid 34252204)
68. Jinnin M, Ihn H, Mimura Y, Asano Y, Tamaki K. Involvement of the constitutive complex formation of c-Ski/ SnoN with Smads in the impaired negative feedback regulation of transforming growth factor b signalling in scleroderma fibroblasts. Arthritis Rheum. 56,1694-1705 (2007) (Pubitemid 46764101)
69. Ishida W, Mori Y, Lakos G et al. Intracellular TGF-b receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest. Dermatol. 126, 1733-1744 (2006) (Pubitemid 44086506)
70. Del Galdo F, Sotgia F, de Almeida CJ et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 58, 2854-2865 (2008)
71. Tan FK, Hildebrand BA, Lester MS et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum. 52, 865-876 (2005) (Pubitemid 40365110)
72. Massague J. TGF-b signal transduction. Annu. Rev. Biochem. 67, 753-791 (1998)
73. Moustakas A, Heldin CH. Non-Smad TGF-b signals. J Cell. Sci. 118, 3573-3584 (2005)
74. Chung L, Fiorentino DF, Benbarak MJ et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum. 60, 584-591 (2009)
75. Distler JH, Jüngel A, Huber LC et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 56, 311-322 (2007) (Pubitemid 46106205)
76. Akhmetshina A, Dees C, Pileckyte M et al. Dual inhibition of c-abl and PDGF receptor signalling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 22, 2214-2222 (2008) (Pubitemid 351948641)
77. Pannu J, Asano Y, Nakerakanti S et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum. 58, 2528-2537 (2008)
78. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest. Dermatol. 124, 886-892 (2005) (Pubitemid 40629086)
79. Jun JB, Kuechle M, Min J et al. Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ. J Invest. Dermatol. 124, 298-303 (2005) (Pubitemid 40175874)
80. Ihn H, Yamane K, Tamaki K. Increased phosphorylation and activation of mitogen-activated protein kinase p38 in scleroderma fibroblasts. J Invest. Dermatol. 125, 247-255 (2005) (Pubitemid 41648157)
81. Sato M, Shegogue D, Gore EA, Smith EA, McDermott PJ, Trojanowska M. Role of p38 MAPK in transforming growth factor b stimulation of collagen production by scleroderma and healthy dermal fibroblasts. J Invest. Dermatol. 118, 704-711 (2002) (Pubitemid 34309993)
82. Wu M, Melichian DS, de la Garza M et al. Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. Am J Pathol. 175, 1041-1055 (2009)
83. Bhattacharyya S, Wei J, Melichian DS, Milbrandt J, Takehara K, Varga J. The transcriptional cofactor Nab2 is induced by TGF-b and suppresses fibroblast activation: physiological roles and impaired expression in scleroderma. PLoS ONE 26(4), e7620 (2009)
84. Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res. Ther. 9(Suppl. 2), S2 (2007)
85. Shi-wen X, Kennedy L, Renzoni EA et al. Endothelin is a downstream mediator of pro-fibrotic responses to transforming growth factor b in human lung fibroblasts. Arthritis Rheum. 56, 4189-4194 (2007) (Pubitemid 350262347)
86. Denton CP, Abraham DJ. Transforming growth factor-b and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin. Rheumatol. 13, 505-511 (2001) (Pubitemid 33070969)
87. Stratton R, Shiwen X, Martini G et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest. 108, 241-250 (2001) (Pubitemid 32656248)
88. Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J. Med 354, 2667-2676 (2006)
89. Classen JF, Henrohn D, Rorsman F et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum. 60, 1137-1144 (2009)
90. Loizos N, Lariccia L, Weiner J et al. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor a in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum. 60, 1145-1151 (2009)
91. Hogaboam CM, Bone-Larson CL, Lipinski S et al. Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1-and Th2-type pulmonary granuloma models. J Immunol. 163, 2193-2201 (1999) (Pubitemid 29382227)
92. Chizzolini C, Parel Y, Scheja A, Dayer JM. Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts. Arthritis Res. Ther. 8, R10 (2006)
93. Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL. Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum. 44, 1382-1386 (2001) (Pubitemid 32537537)
94. Distler JH, Jüngel A, Caretto D et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its pro-fibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum. 54, 214-225 (2006) (Pubitemid 43122204)
95. Granstein RD, Flotte TJ, Amento EP. Interferons and collagen production. J Invest. Dermatol. 95, 75S-80S (1990)
96. Desmoulière A, Rubbia-Brandt L, Abdiu A, Walz T, Macieira-Coelho A, Gabbiani G. A-smooth muscle actin is expressed in a subpopulation of cultured and cloned fibroblasts and is modulated by g-interferon. Exp. Cell. Res. 201, 64-73 (1992)
97. Santiago B, Galindo M, Palao G, Pablos JL. Intracellular regulation of Fas-induced apoptosis in human fibroblasts by extracellular factors and cycloheximide. J Immunol. 172, 560-566 (2004) (Pubitemid 38020513)
98. Lemaire R, Farina G, Bayle J et al. Antagonistic effect of the matricellular signalling protein CCN3 on TGF-b-and Wnt-mediated fibrillinogenesis in systemic sclerosis and Marfan syndrome. J Invest. Dermatol. 130, 1514-1523 (2010)
99. Castelino FV, Seiders J, Bain G et al. Genetic deletion or pharmacologic antagonism of LPA(1) ameliorates dermal fibrosis in a scleroderma mouse model. Arthritis Rheum. 63(5), 1405-1415 (2011)
100. Oga T, Matsuoka T, Yao C et al. Prostaglandin F(2a) receptor signalling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-b. Nat Med 15, 1426-1430 (2009)
101. Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ. Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology (Oxford). 49, 259-263 (2010)
102. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks pro-fibrotic responses through peroxisome proliferator-activated receptor-g. Am J Pathol. 174, 519-533 (2009)
103. Maurer B, Stanczyk J, Jüngel A et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 62, 1733-1743 (2010)
104. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 54, 2271-2279 (2006) (Pubitemid 44051084)
105. Kubo M, Czuwara-Ladykowska J, Moussa O et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol. 163, 571-578 (2003)